Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity
| Autor: | Eman A Attallah, Ameera G Abdelhameed, Rania M. Bassiouny, Walid M Gaafar, Ahmed G Elgharieb, Amgad El Nokrashy, Mohamed Reda Bassiouny |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
genetic structures Birth weight Angiogenesis Inhibitors Gestational Age Retinal Neovascularization chemistry.chemical_compound Ophthalmology Ranibizumab medicine Humans Retinopathy of Prematurity Child Retrospective Studies business.industry General Arts and Humanities Postmenstrual Age Infant Newborn Gestational age Retinal detachment Infant Retinopathy of prematurity Retinal Retrospective cohort study medicine.disease eye diseases Sensory Systems Treatment Outcome chemistry Intravitreal Injections sense organs business medicine.drug |
| Zdroj: | Eye (London, England). 36(11) |
| ISSN: | 1476-5454 |
| Popis: | Background To assess reactivation after initial intravitreal injection of ranibizumab (IVR) for type 1 retinopathy of prematurity (ROP) or worse and the outcome following reinjection of ranibizumab for this reactivation. Methods This retrospective study was performed on infants screened for ROP between March 2013 and February 2020 in Mansoura University Children Hospital, Mansoura, Egypt. Infants treated with ranibizumab 0.25 mg/0.025 mL were identified for review of their clinical outcomes. Data of infants with reactivation and IVR re-injection were analysed. Results A total of 2318 infants were screened for ROP, 115 (5%) infants (216 eyes) with a mean gestational age of 30 ± 2.5 weeks and mean birth weight of 1290 ± 355.2 g received IVR at mean postmenstrual age (PMA) of 38 ± 3.1 weeks. All treated eyes demonstrated initial regression of ROP. However, ROP reactivation occurred in 5 (2.3%) eyes of 3 patients, at an average of 9.6 ± 2.9 weeks after treatment. None of these eyes had retinal detachment. A second dose IVR was administered and all five eyes showed regression with complete retinal vascularisation, at a mean PMA of 60 ± 5.1 weeks. Conclusions IVR is beneficial as an initial and subsequent treatment for type 1 ROP or APROP. A long-term follow-up until complete retinal vascularisation is recommended to avoid disease reactivation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink